The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of shares of Common Stock outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per share of Common Stock after giving consideration to all potentially dilutive shares of common stock, including options to purchase common stock and warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential shares of Common Stock have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.

The following table sets forth the computation of basic and diluted net loss per share for the three and six months ended June 30, 2026 and 2025:


	Three Months Ended June 30,						Six Months Ended June 30,
	2026			2025			2026			2025
Numerator:
Net loss from continuing operations	$	(33,993	)	$	(75,157	)	$	(60,699	)	$	(83,619	)
Income from discontinued operations		—			—			19,585			—
Less: Net loss attributable to noncontrolling interests		(408	)		(95	)		(652	)		(110	)
Net loss attributable to ASP Isotopes Inc. shareholders	$	(33,585	)	$	(75,062	)	$	(40,462	)	$	(83,509	)
Denominator:
Weighted average common stock outstanding, basic and diluted		122,715,677			73,009,938			121,860,483			71,256,809
Net (loss) income per share, basic and diluted:
Continuing operations	$	(0.28	)	$	(1.03	)	$	(0.50	)	$	(1.17	)
Discontinued operations	$	-		$	-		$	0.16		$	-
Attributable to ASP Isotopes Inc. shareholders	$	(0.27	)	$	(1.03	)	$	(0.33	)	$	(1.17	)

The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:


	As of June 30,
	2026		2025
Options to purchase common stock		730,565		2,431,000
Restricted stock		6,879,423		4,754,156
Warrants to purchase common stock		69,778		221,519
Total shares of common stock equivalents		7,679,766		7,406,675